Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sunshine Biopharma ( (SBFM) ) has provided an announcement.
On February 18, 2026, Sunshine Biopharma Inc. reported that CEO Dr. Steve N. Slilaty, as majority voting shareholder, approved a written consent authorizing the board to implement a reverse split of the company’s common stock at a ratio of up to 1-for-10. The board has discretion on whether to execute the reverse split and at what exact whole-number ratio within that range, with the shareholder consent becoming effective 20 days after the definitive information statement is mailed to stockholders.
The move underscores the high concentration of control in Dr. Slilaty’s hands and provides management with flexibility to adjust the share structure, which could have implications for the stock’s trading price, liquidity, and the company’s capital markets strategy. Minority shareholders will be subject to the board’s eventual decision on if and how the reverse split is carried out, once the consent becomes effective under the prescribed notice period.
The most recent analyst rating on (SBFM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Sunshine Biopharma stock, see the SBFM Stock Forecast page.
Spark’s Take on SBFM Stock
According to Spark, TipRanks’ AI Analyst, SBFM is a Neutral.
Sunshine Biopharma’s overall stock score is primarily impacted by its financial performance and valuation. The company faces significant profitability and cash flow challenges, reflected in a low financial performance score. The technical analysis indicates a bearish trend, while the negative P/E ratio and lack of dividend yield result in a poor valuation score. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on SBFM stock, click here.
More about Sunshine Biopharma
Sunshine Biopharma Inc. is a biopharmaceutical company, with its stock structured to include a large concentration of voting power held by its chief executive officer. Dr. Steve N. Slilaty controls approximately 96% of the total voting power of the company’s stockholders, effectively giving him decisive influence over major corporate actions.
Average Trading Volume: 45,430
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.79M
For a thorough assessment of SBFM stock, go to TipRanks’ Stock Analysis page.